Hyperinsulinaemic hypoglycaemia caused by over functioning beta cells is a potentially lethal disease especially to infants. Our highly-innovative integrated therapy platform will allow diagnosis and guide therapeutic intervention.
|
Personalized diagnosis and treatment of hyperinsulinemic hypoglycaemia caused by beta-cell pathology |
|
1st April 2014 |
|
4 years |
|
€ 6 million |
|
Stichting Katholieke Universiteit, Radboud University Nijmegen Medical School – Prof. Martin Gotthardt |
31 May 2018 |
Final Summary Report ready for you to read! |
31 March 2018 |
The BetaCure project has ended successfully |
| All events |
© 2020 BetaCure Legal Disclaimer
 |
This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602812. This website reflects only the authors' view and the European Commission is not responsible for any use that may be made of the information it contains. |